Back to search

Peptide record

TPDB23238

Antibacterial Anticancer Toxicity modified_plain modified
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB23238
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia
modified_plain
Yes
A 5-aa modified multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Modified, details unspecified
Sequence
LXLPL
Physicochemical Analysis
C23H42N4O5
ARNDCEQGHIKMFSTWYV
L
454.61
6.02
0
0
3
-0
-1.23
1.960
234.00
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
3
L
0
K
0
M
0
F
1
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 3 K: 0 M: 0 F: 0 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
5
C23H42N4O5
454.61
6.02
-0
-1.23
1.960
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
Toxicity
>40 µg/mL
Cytotoxic
IC50 | >40 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Synthesis of Marine Cyclopeptide Galaxamide Analogues as Potential Anticancer Agents | Mar Drugs | 2022
Evidence 2 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Mar Drugs. 2022 Feb 22 20(3):159.